The significant guidance cut and delayed cash-flow breakeven suggest the business is in a correction phase. Watch for further revenue shortfalls in H2 2026 and clinical utility study results/FDA decision on LucentAD Complete as potential catalysts. The new commercial leadership has not yet proven results.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $2.42entry
- T+1 · 3mo ago +8.47%α +8.79% · $2.63
- T+5 · 3mo ago +20.66%α +20.71% · $2.92
- T+20 · 2mo ago +12.81%α +13.72% · $2.73
- T+60 · 14d ago +21.49%α +23.90% · $2.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Quanterix Q2 2026 revenue of $32.9M missed consensus estimates of $37.5M by 12.3%, driven by execution challenges and market softness. The company slashed full-year 2026 guidance to $142-148M from $169-174M, recorded a $26.9M goodwill impairment, and pushed cash-flow breakeven to 2027.
Key Financial Metrics
Key Facts
- Revenue of $32.9M missed the $37.5M consensus estimate by 12.3%
- GAAP gross margin fell to 38.5% from 40.9% a year ago
- Net loss widened to $48.9M vs $30.0M in Q2 2025, including a $26.9M goodwill impairment
- EPS of ($1.04) per share on 47.2M shares, versus consensus of ($0.41) on a different share count, GAAP EPS not directly comparable to consensus
- Full-year 2026 revenue guidance slashed to $142-148M from $169-174M
- Cash-flow breakeven pushed to 2027 from H2 2026; year-end cash forecast lowered to ~$80M from ~$100M
- Pro-forma revenue (including Akoya pre-acquisition) declined 23% year-over-year
- Completed ERP integration and realized $85M in annualized cost synergies from Akoya acquisition
- Appointed Jim Gute as Chief Commercial Officer; named other senior leaders
Financial Impact
Revenue guidance reduced by ~16% at midpoint ($145M vs $171.5M prior midpoint), implying $10M+ in lost revenue vs prior expectations. Cash balance expected to decline to ~$80M by year-end 2026 from $96.9M.
Risk Factors
- Continued revenue shortfall from execution challenges and weak academic/pharma end markets
- Cash burn could accelerate if revenue does not recover, potentially requiring dilutive financing
- Failure to achieve 2027 cash-flow breakeven target
- Goodwill impairment signals potential for further impairments on remaining goodwill
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001503274-26-000035 |
| Exhibit: ex993-qtrxx20260630.htm | 0001503274-26-000035 |
| Document: q2-26earningspresentatio.htm | 0001503274-26-000035 |
| Document: qtrx-20260810.htm | 0001503274-26-000035 |
| Document: 0001503274-26-000035-index-headers.html | 0001503274-26-000035 |
| Document: 0001503274-26-000035-index.html | 0001503274-26-000035 |
| Document: 0001503274-26-000035.txt | 0001503274-26-000035 |
| 8-K Data (Synthetic) | 0001503274-26-000035 |
Track record
7 reports on QTRX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $3.28 Now $2.84 −13.41% settles Nov 17
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $3.38 to $2.84 Now $2.84 +15.98% ▲ +15.98% +14.28% vs SPY
- Aug 10, 202614w ago 8-K Bearish 8/10 Viewing Entry $2.42 to $2.92 Now $2.84 −17.36% ▼ −20.66% −20.71% vs SPY
- Jun 17, 202621w ago Institutional Cluster Bullish 5/10 Entry $2.88 to $3.78 Now $2.84 −1.39% ▲ +31.25% +32.29% vs SPY
- Jun 9, 202622w ago 8-K Neutral 3/10 Entry $3.09 to $3.10 Now $2.84 −8.09% ▲ +0.32% −2.09% vs SPY
- May 26, 202624w ago 8-K Neutral 2/10 Entry $2.65 to $3.53 Now $2.84 +7.17% ▲ +33.21% +32.74% vs SPY
- May 8, 202627w ago DEFA14A Neutral 2/10 Entry $2.80 to $2.52 Now $2.84 +1.43% ▼ −10.00% −9.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers